Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer

被引:41
|
作者
Asuthkar, Swapna [1 ]
Stepanova, Victoria [4 ]
Lebedeva, Tatiana [4 ]
Holterman, AiXuan L. [2 ]
Estes, Norman [2 ]
Cines, Douglas B. [4 ]
Rao, Jasti S. [1 ]
Gondi, Christopher S. [3 ]
机构
[1] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA
[2] Univ Illinois, Coll Med Peoria, Dept Surg, Peoria, IL 61605 USA
[3] Univ Illinois, Coll Med Peoria, Dept Med, Peoria, IL 61605 USA
[4] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-STROMAL INTERACTIONS; GLIOMA-CELL INVASION; DOWN-REGULATION; RECEPTOR UPAR; SIDE POPULATION; ANTISENSE UPAR; HAIRPIN RNA; EXPRESSION; GROWTH;
D O I
10.1091/mbc.E12-04-0306
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is almost always lethal. One of the underlying reasons for this lethality is believed to be the presence of cancer stem cells (CSC), which impart chemoresistance and promote recurrence, but the mechanisms responsible are unclear. Recently the poor prognosis of PDAC has been correlated with increased expression of urokinase plasminogen activator (uPA). In the present study we examine the role of uPA in the generation of PDAC CSC. We observe a subset of cells identifiable as a side population (SP) when sorted by flow cytometry of MIA PaCa-2 and PANC-1 pancreatic cancer cells that possess the properties of CSC. A large fraction of these SP cells are CD44 and CD24 positive, are gemcitabine resistant, possess sphere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness. Increased tumorigenicity and gemcitabine resistance decrease after suppression of uPA. We observe that uPA interacts directly with transcription factors LIM homeobox-2 (Lhx2), homeobox transcription factor A5 (HOXA5), and Hey to possibly promote cancer stemness. uPA regulates Lhx2 expression by suppressing expression of miR-124 and p53 expression by repressing its promoter by inactivating HOXA5. These results demonstrate that regulation of gene transcription by uPA contributes to cancer stemness and clinical lethality.
引用
收藏
页码:2620 / 2632
页数:13
相关论文
共 50 条
  • [31] Urokinase-like plasminogen activator receptor (uPA-R) expression on disseminated breast cancer cells
    Tögel, F
    Kröger, N
    Gieseking, F
    Lindner, C
    Jänicke, F
    Zander, AR
    Krüger, WH
    BONE MARROW TRANSPLANTATION, 1999, 23 : S151 - S151
  • [32] Expression of urokinase plasminogen activator (uPA) and the uPA receptor (uPAR) in myeloma cells.
    Hjertner, O
    Westin, J
    BLOOD, 1999, 94 (10) : 549A - 549A
  • [33] Imaging Active Urokinase Plasminogen Activator in Prostate Cancer
    LeBeau, Aaron M.
    Sevillano, Natalia
    Markham, Kate
    Winter, Michael B.
    Murphy, Stephanie T.
    Hostetter, Daniel R.
    West, James
    Lowman, Henry
    Craik, Charles S.
    VanBrocklin, Henry F.
    CANCER RESEARCH, 2015, 75 (07) : 1225 - 1235
  • [34] Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells
    Nishimura, K
    Matsumiya, K
    Miura, H
    Tsujimura, A
    Nonomura, N
    Matsumoto, K
    Nakamura, T
    Okuyama, A
    INTERNATIONAL JOURNAL OF ANDROLOGY, 2003, 26 (03): : 175 - 179
  • [35] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [36] Urokinase type plasminogen activator (uPA) is a predictor of malignancy in pancreaticobiliary malignancies
    Gibbs, JF
    Singh, P
    Schlieman, MG
    Saxena, R
    Martinick, M
    Corasanti, J
    Harvey, S
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 53 - 53
  • [37] Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic cancer is correlated with shorter survival
    Friess, H
    Cantero, D
    Zimmermann, A
    Korc, M
    Buchler, MW
    GASTROENTEROLOGY, 1996, 110 (04) : A389 - A389
  • [38] Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis
    Leonardi, A
    Brun, P
    Sartori, MT
    Cortivo, R
    DeDominicis, C
    Saggiorato, G
    Abatangelo, G
    Secchi, AG
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (04) : 1364 - 1370
  • [39] Exploring the activity and inhibition of urokinase-type plasminogen activator (UPA)
    Song, Harriet J.
    Torres-Paris, Constanza
    Komives, Elizabeth A.
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 348A - 348A
  • [40] Downregulation of urokinase-type plasminogen activator inhibitor (PAI-1) in pancreatic cancer
    Metzger, R.
    Warnecke-Eberz, U.
    Prenzel, K. L.
    Baldus, S. E.
    Brabender, J.
    Vallboehmer, D.
    Hoelscher, A. H.
    Schneider, P. M.
    EJC SUPPLEMENTS, 2006, 4 (06): : 27 - 27